Collectively, these data indicate that the prognostic relevance of YY1 in HCC is most pronounced in the context of anti‐PD‐1 therapy, whereas its predictive value is markedly attenuated under nonimmunotherapy regimens. This evidence concerns the gene YY1 and hepatocellular carcinoma.